ReviewThe quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...2020
Current and novel radiopharmaceuticals for imaging cardiovascular inflammation.
Review in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Beyond perfusion: a review of peptide radiopharmaceuticals for cardiovascular imaging.Npj imaging · 2025Review
- Preclinical evaluation of high-resolution CT,European journal of nuclear medicine and molecular imaging · 2025Article
- Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Nuclear Methods for Immune Cell Imaging: Bridging Molecular Imaging and Individualized Medicine.Circulation. Cardiovascular imaging · 2023Article
- Recent Advances in Cardiovascular Diseases Research Using Animal Models and PET Radioisotope Tracers.International journal of molecular sciences · 2022Review
- Emerging Nuclear Medicine Imaging of Atherosclerotic Plaque Formation.Journal of imaging · 2022Review
- Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation.Scientific reports · 2022Article
- Fantastic voyage: Catheter-based quantification of tracer distribution on a miniature scale.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The Latest Advances in Imaging Crosstalk Between the Immune System and Fibrosis in Cardiovascular Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
- Assessment of ultrasmall nanocluster for early and accurate detection of atherosclerosis using positron emission tomography/computed tomography.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- Delineating the Role of Macrophages in Cardiovascular Disease: How Specific Do We Need to Be?Circulation. Cardiovascular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide despite advances in diagnostic technologies and treatment strategies. The underlying cause of most CVD is atherosclerosis, a chronic disease driven by inflammatory reactions. Atherosclerotic plaque rupture could cause arterial occlusion leading to ischemic tissue injuries such as myocardial infarction (MI) and stroke. Clinically, most imaging modalities are based on anatomy and provide limited information about the on-going molecular activities affecting the vulnerability of atherosclerotic lesion for risk stratification of patients. Thus, the ability to differentiate stable plaques from those that are vulnerable is an unmet clinical need. Of various imaging techniques, the radionuclide-based molecular imaging modalities including positron emission tomography and single-photon emission computerized tomography provide superior ability to noninvasively visualize molecular activities in vivo and may serve as a useful tool in tackling this challenge. Moreover, the well-established translational pathway of radiopharmaceuticals may also facilitate the translation of discoveries from benchtop to clinical investigation in contrast to other imaging modalities to fulfill the goal of precision medicine. The relationship between inflammation occurring within the plaque and its proneness to rupture has been well documented. Therefore, an active effort has been significantly devoted to develop radiopharmaceuticals specifically to measure CVD inflammatory status, and potentially elucidate those plaques which are prone to rupture. In the following review, molecular imaging of inflammatory biomarkers will be briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.